FDA Grants Breakthrough Device Designation for CRISPR Blood Test for Tuberculosis
IntelliGenome’s CRISPR-TB Blood Test, designed to detect Mycobacterium tuberculosis cfDNA, received FDA Breakthrough Device Designation.
Read MorePosted by Andy Lundin | Jan 24, 2025 | Molecular Diagnostics |
IntelliGenome’s CRISPR-TB Blood Test, designed to detect Mycobacterium tuberculosis cfDNA, received FDA Breakthrough Device Designation.
Read MorePosted by Andy Lundin | Jan 24, 2025 | Covid 19 |
Researchers identified a unique blood protein signature for long COVID in children, enabling AI-powered diagnosis with 93% accuracy.
Read MorePosted by Andy Lundin | Jan 23, 2025 | Leukemia, Sequencing Systems |
OGT’s SureSeq Myeloid MRD Panel offers a NGS solution for ultra-sensitive detection of MRD biomarkers in acute myeloid leukemia.
Read MorePosted by Andy Lundin | Jan 23, 2025 | Company News |
HealthTrackRx opened a new campus at the UPS Healthcare Labport in Louisville, enabling next-morning infection diagnostics nationwide.
Read MorePosted by Andy Lundin | Jan 22, 2025 | Unknown Origin & Other Cancer Types |
A biomarker-based algorithm combined with a noninvasive test identifies those at risk for esophageal cancer or precancerous conditions.
Read More